Indeed, a recent meta-analysis of five trials demonstrated that nivolumab and pembrolizumab were correlated with a significant increase of ORR as compared to atezolizumab, while nivolumab was found to associate with a lower incidence of G3-5 AEs in comparison with other anti-PD-1/PD-L1 agents for NSCLC treatment [110]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.